Magnetic seizures: a new hope for schizophrenia without the memory fog?

NCT ID NCT06672588

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study compares Magnetic Seizure Therapy (MST) to standard Electroconvulsive Therapy (ECT) in 80 people with treatment-resistant schizophrenia or schizoaffective disorder. MST uses magnetic pulses to trigger a controlled seizure, aiming to ease symptoms like hallucinations and depression while causing fewer memory problems than ECT. Researchers will track symptom changes, thinking skills, and side effects over the treatment course.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Magnetic Seizure Therapy (MST) device
What this could lead to
If MST works, it could offer a safer, more tolerable alternative to ECT for people with hard-to-treat schizophrenia, reducing symptoms and cognitive side effects.
What could go wrong
This is an early-stage trial with only 80 participants, so results may not apply to everyone. MST may not be as effective as ECT, and risks like seizures or memory issues remain possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOAFFECTIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Psychotic Disorders schizoaffective disorder schizophrenia Schizophrenia, Treatment-Resistant treatment-refractory schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre for Addiction and Mental Health

    RECRUITING

    Toronto, Ontario, M6J 1H4, Canada

  • University of British Columbia Hospital

    RECRUITING

    Vancouver, British Columbia, V6T 2A1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.